JNCE stock forecast
Our latest prediction for Jounce Therapeutics, Inc.'s stock price was made on the Jan. 7, 2020 when the stock price was at 7.78$.
In the short term (2weeks), JNCE's stock price should underperform the market by -5.60%. During that period the price should oscillate between -9.58% and +10.93%.
In the medium term (3months), JNCE's stock price should underperform the market by -6.83%. During that period the price should oscillate between -31.72% and +27.45%.Get email alerts
Create a solid portfolio with JNCE
About Jounce Therapeutics, Inc.
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.
At the moment the company generates 168M USD in revenues.
On its last earning announcement, the company reported a profit of 2.27$ per share.
The book value per share is 3.33$
Three months stock forecastJan. 7, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|